Brands push up Hypera's sales
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Brazil’s Hypera Pharma – formerly known as Hypermarcas – said a rise in group sales of 12.7% to BRL3.64 billion (€898 million) in 2017 had been “mostly derived from the performance of branded products” in the firm’s Branded Prescription and Consumer Health business units.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.